Tag: analysts
COVID antibody drugs from Lilly and Regeneron won’t do much to...
When Eli Lilly won emergency use authorization for its COVID-19 antibody drug, bamlanivimab, earlier this week, beating Regeneron to the finish line in a...
With U.S. elections nearing, European pharma giants brace for potential pricing...
With U.S. presidential and congressional campaigns in full swing, it’s not just Americans anxiously awaiting the results of the upcoming elections. The races could affect European pharma...
Moderna’s COVID-19 vaccine could cruise to $5B in sales—or more, analysts...
Moderna has never scored a commercial approval for any of its drugs or vaccines, but analysts with Jefferies think the company has a winner in...
Where can Biogen turn after mammoth Alzheimer’s blow? The M&A table,...
Biogen investors’ worst fears have come true with the failure of its phase 3 Alzheimer’s prospect, and now, it may be “buy or be...
